A compound of Formula: wherein: Z 1 is N or CR 6 where R 6 is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, or cyano; R 1 is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, or cycloalkyl; R 2 is hydrogen, alkyl, cycloalkyl, halo, cyano, acyl, aminocarbonyl, phenyl or heteroaryl wherein phenyl and heteroaryl is optionally substituted with one, two or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, or haloalkoxy; Ar is phenyl, pyridinyl, pyridazinyl, pyrazinyl, or pyrimidinyl; R 3 is -(alkylene) n -Y-CH=CHR c [where n is 0 or 1, Y is -NR a CO-, -NR a SO 2 -, -CO- or-SO 2 - (where R a is hydrogen or alkyl) and R c is hydrogen, alkyl, NH 2 alkyl, alkylaminoalkyl, or dialkylaminoalkyl] and R 3 is attached to carbon of the phenyl, pyridinyl, pyridazinyl, pyrazinyl, or pyrimidinyl ring that is in meta position to the carbon attaching the aforementioned rings to the azaindole core; R 4 is hydrogen, alkyl, alkoxy, hydroxyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, hydroxyalkoxy, alkoxyalkyl, alkoxyalkyloxy, heterocyclylalkyl optionally substituted with one or two substitutents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl, heterocyclyloxy optionally substituted with one or two substitutents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl, heterocyclylalkyloxy optionally substituted with one or two substitutents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl, aminoalkyl, or aminoalkoxy; and R 5 is hydrogen, alkyl, alkoxy, hydroxyl, halo, haloalkyl, haloalkoxy, or cyano; or a pharmaceutically acceptable salt thereof. Z 1 is N or CR 6 where R 6 is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, or cyano; R 1 is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, or cycloalkyl; R 2 is hydrogen, alkyl, cycloalkyl, halo, cyano, acyl, aminocarbonyl, phenyl or heteroaryl wherein phenyl and heteroaryl is optionally substituted with one, two or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, or haloalkoxy; Ar is phenyl, pyridinyl, pyridazinyl, pyrazinyl, or pyrimidinyl; R 3 is -(alkylene) n -Y-CH=CHR c [where n is 0 or 1, Y is -NR a CO-, -NR a SO 2 -, -CO- or-SO 2 - (where R a is hydrogen or alkyl) and R c is hydrogen, alkyl, NH 2 alkyl, alkylaminoalkyl, or dialkylaminoalkyl] and R 3 is attached to carbon of the phenyl, pyridinyl, pyridazinyl, pyrazinyl, or pyrimidinyl ring that is in meta position to the carbon attaching the aforementioned rings to the azaindole core; R 4 is hydrogen, alkyl, alkoxy, hydroxyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, hydroxyalkoxy, alkoxyalkyl, alkoxyalkyloxy, heterocyclylalkyl optionally substituted with one or two substitutents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl, heterocyclyloxy optionally substituted with one or two substitutents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl, heterocyclylalkyloxy optionally substituted with one or two substitutents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl, aminoalkyl, or aminoalkoxy; and R 5 is hydrogen, alkyl, alkoxy, hydroxyl, halo, haloalkyl, haloalkoxy, or cyano; or a pharmaceutically acceptable salt thereof.